News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Novartis AG’s Onbrez Better Than Pfizer Inc.'s Drug Spiriva In COPD
November 3, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Nov 3 (Reuters) - Swiss drugmaker Novartis AG's (NOVN.VX) lung drug Onbrez reduced breathlessness more effectively than Pfizer's (PFE.N) Spiriva in patients with a deadly lung disease, a late-stage trial found.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
Pfizer
Novartis
MORE ON THIS TOPIC
Diabetes
Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial
September 22, 2026
·
2 min read
·
Annalee Armstrong
Sponsored by AGC Biologics
Beyond Random Integration: Transposase cell line development shortening timeline & boosting titers
September 21, 2026
·
7 min read
·
AGC Biologics
IPO
Electra lights up with $350M IPO for pivotal immune-disease drug development
September 18, 2026
·
1 min read
·
Gabrielle Masson
Neuropsychiatric disorders
Xenon tumbles on voluntary psychiatry hold, but analysts confident in $2B epilepsy opportunity
September 18, 2026
·
4 min read
·
Annalee Armstrong
